Notable Analyst Rating Changes 9/11: (BLCM) (NSC) (TOT) Upgraded; (PBR) (MSI) (FSTR) Downgraded
Tweet Send to a Friend
UPGRADES
Guggenheim upgrades Bellicum Pharmaceuticals (Nasdaq: BLCM) from Neutral to Buy with a price target of $38.BofA/Merrill Lynch moves Norfolk ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Guggenheim upgrades Bellicum Pharmaceuticals (Nasdaq: BLCM) from Neutral to Buy with a price target of $38.BofA/Merrill Lynch moves Norfolk ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
